Terbin 1% (Topical Spray)
30 ml bottle: ৳ 600.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Terbinafine hydrochloride |
| Company | Opsonin pharma ltd |
| Also available as |
Title
- Terbinafine Antifungal Medicine
Categories
- Medicine
- Health & Wellness
- Antifungal
Description
- Terbinafine medicine for the treatment of fungal infections
Dosage And Administration
- Dosage instructions for tablets, granules, cream, and spray
Indications
- Indications for terbinafine tablet, granules, cream, and spray
Pharmacology
- Pharmacological action of terbinafine - inhibits biosynthesis of Ergosterol via inhibition of Squalene Epoxidase enzyme
Interaction
- Inhibitor of the CYP450 2D6 isozyme with implications for certain drug classes
Contraindications
- Patients hypersensitive to terbinafine should not use tablet or cream
Side Effects
- Reported adverse events such as gastrointestinal symptoms, liver test abnormalities, rashes, and taste disturbances
Pregnancy And Lactation
- Recommendations for use of terbinafine during pregnancy and lactation
Precautions And Warnings
- Liver failure warnings and precautions for patients with chronic or active liver disease
Use In Special Populations
- Not established for pediatric patients, no evidence of different effects in the elderly
Overdose Effects
- Limited clinical experience regarding overdose with terbinafine tablets
Therapeutic Class
- Belongs to the class of antifungal preparations
Storage Conditions
- Storage instructions for maintaining medicine quality
Body Weight Dosage
- Different dosages based on body weight for terbinafine granules
Treatment Duration
- Duration of treatment for different types of fungal infections
Mode Of Action
- Details on how terbinafine works at a molecular level
Drug Metabolism
- Inhibition of the CYP450 2D6 isozyme with implications for drug metabolism
Topical Application
- Instructions for applying terbinafine cream and spray
Skin Infections
- Indicated for fungal infections of the skin caused by specific microorganisms
Spray Application
- Instructions for applying terbinafine 1% spray for various conditions
Symptomatic Hepatic Injury
- Possible occurrence of symptomatic hepatic injury as an adverse reaction
Systemic Conditions
- Possible association with serious hepatic events in patients with serious underlying systemic conditions
External Use Only
- Indication that terbinafine cream is for external use only
Eye Contact
- Warning to avoid contact with eyes when using terbinafine cream
Patients Monitoring
- Recommendation for monitoring serum transaminase levels before taking terbinafine tablets
Pretreatment Assessment
- Assessment of pre-existing liver disease before prescribing terbinafine
Hepatotoxicity
- Potential occurrence of hepatotoxicity in patients with and without pre-existing liver disease
Safety And Efficacy
- Need for established safety and efficacy data in pediatric patients
Elderly Patients
- Lack of evidence for different dosages or side-effects in elderly patients
Drug Overdose
- Clinical experience and symptoms associated with overdose of terbinafine tablets
Therapeutic Use
- Application for the treatment of onychomycosis and tinea infections
Inhibitory Action
- Mechanism of inhibiting biosynthesis of Ergosterol as an essential component of fungal cell membrane
Biochemical Evidence
- Need for discontinuation of treatment in case of biochemical or clinical evidence of liver injury
Storage Temperature
- Instructions for storing the medicine in a cool and dry place below 30°C
Light Protection
- Recommendation to protect the medicine from light during storage
Anaphylaxis
- Possibility of severe allergic reactions, including anaphylaxis, as an adverse event
Liver Transplant
- Rare reported cases of liver failure leading to liver transplant in association with terbinafine use
Squalene Accumulation
- Fungal cell death caused by increased membrane permeability from Squalene accumulation
Clinical Significance
- Uncertainty regarding the clinical significance of in vitro data on terbinafine's activity
Potential Risk
- Advice to avoid terbinafine administration in pregnant women unless potential benefits outweigh potential risk
Breast Milk
- Presence of terbinafine in breast milk
Nursing Mothers
- Recommendation against terbinafine treatment in nursing mothers due to presence in breast milk
Fertility Studies
- No adverse effects observed in foetal toxicity and fertility studies in animals
Hepatic Events
- Possible manifestation of severe hepatic events in patients with active or chronic liver disease
Progressive Skin Rash
- Need for discontinuation of treatment in case of progressive skin rash
Hepatic Disease
- Not recommended for patients with chronic or active liver disease
Elderly Experience
- Lack of evidence suggesting different experience in elderly patients
Limited Clinical Experience
- Limited information available regarding clinical experience with terbinafine tablet overdose
Therapeutic Administration
- Instructions for administering the terbinafine tablet, granules, cream, and spray
Animal Reproduction Studies
- Caution regarding the predictiveness of animal reproduction studies for human response
Hypersensitivity
- Contraindication for individuals hypersensitive to terbinafine
Clinical Symptoms Relief
- Expectation for relief of clinical symptoms within a few days of treatment
Liver Disease
- Assessment of pre-existing liver disease before prescribing terbinafine
Nail Onychomycosis
- Specific dosage and treatment duration for onychomycosis of the toenail or fingernail
Pityriasis Versicolor
- Indication for the treatment of pityriasis versicolor due to specific microorganisms
Treatment Cessation
- Need for cessation of treatment after mycological cure for optimal clinical effect
Indication Specifics
- Specific indications for terbinafine tablet, granules, cream, and spray
Fungal Infections
- Indication for the treatment of fungal infections caused by specific microorganisms
Skin Application
- Instruction for applying terbinafine cream to the affected skin and surrounding area
Clinical Effect
- Optimal clinical effect expected some months after mycological cure and treatment cessation